Moderna Jumps 7% While Melanoma Vaccine Data Looms; Bristol Myers Squibb Rises 5%, Pfizer Inches Higher

Impact · against what's priced in

The upcoming October 24 melanoma data is a binary catalyst for Moderna and a potential growth accelerator for Merck, though Moderna's current price already aggressively bets on a successful outcome. While Moderna's stock is surging on anticipation, the news confirms the high-stakes dependency on this specific trial to offset massive quarterly losses.

MRK+0.20

Challenges what's priced in

The price assumes